Sector News

David Meline, Amgen’s Chief Financial Officer, to retire

October 23, 2019
Life sciences

Amgen today announced the planned retirement of David W. Meline, who has served as the company’s executive vice president and chief financial officer (CFO) since 2014. Meline will serve as CFO through the end of 2019 and remain at the company into the second quarter of 2020 to help ensure a smooth transition of his responsibilities. The company also announced that Peter H. Griffith has joined Amgen as executive vice president, Finance, and will be Meline’s successor as CFO as of Jan. 1, 2020.

“I am grateful to David for the many contributions he has made to Amgen’s success,” said Robert A. Bradway, chairman and chief executive officer. “David has played an essential role in the enterprise-wide transformation that has enabled Amgen to deliver outstanding financial performance to our shareholders, while also investing heavily in new product launches, research and development, and global expansion. Additionally, under David’s leadership, Amgen has built and embedded a set of productivity capabilities throughout our organization that position us for continued success in a highly dynamic external environment.”

Meline joined Amgen from 3M, where he was senior vice president and CFO. Previously, Meline held numerous senior-level roles at General Motors, including vice president and CFO for GM North America.

“A hallmark of Amgen’s nearly 40-year history has been well-planned transitions of key leadership roles,” Bradway said. “I am delighted to welcome Peter to Amgen. His extensive global experience and financial skills will be instrumental to our strategy for investing in innovation to drive long-term growth. I am pleased that David will remain with Amgen into 2020 to work with Peter and ensure a smooth transition.”

Griffith joins Amgen from Sherwood Canyon Group, LLC, a private equity and advisory firm, where he served as president. Previously, he retired from EY (formerly Ernst & Young), a leader in assurance, tax, transaction and advisory services, after a distinguished career there, including almost 22 years as a partner. Most recently, Griffith served as EY’s Global Vice Chair, Corporate Development with responsibility for driving the firm’s international growth and expanding its capabilities worldwide. He previously served as EY’s Global Managing Partner, Finance and Corporate Development and, before that, as Global Managing Partner, Operations and Finance during a time when the organization grew annual revenues more than 25% to over $27 billion. This latter role included the Finance and Accounting, Corporate Development, Tax, and Treasury functions. During his tenure, Griffith served on the EY Global Executive Board, the EY Americas Executive Board, and the Executive Board of Ernst & Young LLP. Prior to EY, he was Managing Director and Head of Investment Banking at Wedbush Securities.

Source: Amgen

Related News

April 7, 2020

Coronavirus tracker: Alexion launches trial; Lilly, BMS extend help; Trump offers to treat British PM

Life sciences

Two biopharmas, Alexion Pharmaceuticals and Karyopharm, are trialing possible treatments while Eli Lilly and Bristol Myers Squibb are offering to help the unemployed stay on their meds. Meanwhile, President Donald […]

April 2, 2020

Novartis terminates $1bn Sandoz US deal with Aurobindo

Life sciences

Novartis and Aurobindo Pharma USA have signed a mutual agreement to terminate their deal covering the Sandoz US generic oral solids and dermatology businesses. In September 2018, Novartis entered an […]

April 2, 2020

Driving value from genomics

Life sciences

The cost of taking a drug to market – estimated to be approximately $2.6 billion – combined with increasingly tight healthcare budgets, has put intense pressure on R&D teams. Genomics, […]